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Background
Axitinib, an inhibitor of vascular endothelial growth fac-
tor receptors (VEGFRs), is approved for second-line
treatment of advanced renal cell carcinoma (aRCC).
Pembrolizumab is a humanized monoclonal antibody
that blocks binding of the immune-checkpoint receptor
programmed death-1 (PD 1) to its ligands (PD-L1/2).
Combination treatment with PD-1 and VEGFR inhibi-
tors has shown benefit in aRCC, but increased toxicity
has been observed. This ongoing Phase Ib study
(NCT02133742) is assessing safety and tolerability of
axitinib plus pembrolizumab in treatment-naïve patients
with aRCC to estimate the maximum tolerated dose
(MTD) and recommended Phase II dose (RP2D).
Methods
Eligible patients have clear-cell aRCC, primary tumor
resection, ≥1 measurable lesion, Eastern Cooperative
Oncology Group performance status 0/1, no pre-existing
uncontrolled hypertension, and no prior systemic ther-
apy for aRCC; tumor biospecimens are mandatory.
Axitinib is administered orally (starting dose: 5 mg
twice daily) beginning on day –7; pembrolizumab is
administered intravenously (2 mg/kg) on day 1 of each
3-week cycle. MTD was estimated by modified toxicity
probability interval method. Tumors are assessed per
Response Evaluation Criteria in Solid Tumors v1.1 at
baseline, week 12, and every 6 weeks thereafter. Primary
endpoint is dose-limiting toxicities (DLTs) during the
first 2 cycles. Secondary endpoints include safety, tumor
response, and biomarkers.
Results
As of June 23, 2015, 11 patients (8 males; mean age 61
years) were enrolled; 1 was not evaluable for DLTs.
Three DLTs were reported: transient ischemic attack
(TIA; n=1) and < 75% of planned axitinib dose received
due to treatment-related toxicity (n=2). MTD and RP2D
were determined to be axitinib 5 mg twice daily plus
pembrolizumab 2 mg/kg every 3 weeks. Ten patients
remain on treatment (3 patients with DLTs were admi-
nistered reduced axitinib doses) and progression-free.
Five patients have had confirmed partial responses;
5 have stable disease with 4–33% tumor shrinkage.
Common all-grade adverse events were diarrhea and
hypothyroidism (n=6 each) and arthralgia, fatigue, and
headache (n=4 each); 2 patients had increased hepatic
transaminases (alanine aminotransferase and aspartate
aminotransferase). Grade 3/4 adverse events were head-
ache, increased alanine aminotransferase and aspartate
aminotransferase, hyperuricemia, acute cholecystitis, and
TIA (n=1 each). Only 1 of 9 evaluable tumor biospeci-
mens was PD-L1+; this patient had stable disease.
Conclusions
Preliminary results indicate axitinib plus pembrolizumab
is well tolerated at standard doses of each agent and
exhibits antitumor activity in treatment-naïve patients
with aRCC. Additional patients are being enrolled to
confirm the RP2D and further evaluate safety and activ-
ity of this combination.
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